Epigenica raises $2.2M to drive shift in personalized medicine

Stockholm-based Epigenica AB, a pioneer in high-throughput epigenetic screening tools and solutions, has closed a $2.2 million round to fuel its growth and commercial expansion across key markets.

Advances in RNA, protein, and metabolite analysis has driven the rise of multiomics, offering a more comprehensive view of biological systems. Now epigenetics is emerging as a critical next layer, providing unique insights into how lifestyle and environmental factors influence gene activity, ultimately shaping disease outcomes and treatment strategies.

Epigenica’s proprietary EpiFinder platform enables simultaneous analysis of multiple epigenetic markers across a large number of samples with exceptional resolution, and efficiency, well-suited for drug discovery and drug development.

Mohamad Takwa, CEO of Epigenica, shared:

Since Epigenica’s founding, we’ve refined our technology into a broad portfolio of products serving a diverse range of epigenetics applications. We anticipate a number of significant product launches in the coming year that will enable our customers to improve and expand their research. I’m thrilled to welcome Voima Ventures, Navigare Ventures, and Leksell Social Ventures, and proud of the ongoing confidence and trust expressed by our current shareholders. This funding is a strong validation of our scientific and commercial progress.

The round was led by Voima Ventures, a Nordic early-stage investor that specialises in supporting science-based solutions. Deeptech investor Navigare Ventures, social impact-focused Leksell Social Ventures, and current shareholder Almi Invest also participated in the round. 

Stina Wallmark, Voima Ventures’ Investment Director, said:

The field of epigenetics, which studies how our lifestyle and environment impact the way our genes work, holds transformative potential in areas like oncology, longevity and drug development. Epigenica enables fast, scalable, and affordable analysis of epigenetic biomarkers, helping researchers fully unlock the potential of multi-omics in the search for new diagnostics and therapies.

This funding will accelerate the development and commercialisation of Epigenica’s flagship products, including the already available EpiFinder Genome and upcoming EpiFinder Global and EpiFinder cNUC kits. It will also support the build-out of the company’s service offering and data infrastructure, as well as its expansion into the US market.